細胞療法領域的合作與授權協議（2016-2025）

本報告全面深入分析了細胞療法領域的合作與許可協議（2016-2025），並以前所未有的方式呈現了全球領先的生物製藥公司簽署的細胞療法相關協議。

這份經過全面修訂和更新的報告提供了2016年至2025年細胞療法交易的詳細資訊。

本報告詳細分析了企業簽署細胞療法協議的原因和方式。這些協議通常包含多個組成部分，從合作研發開始，直到最終的商業化。

本報告涵蓋了研究、開發、探索和授權方面的合作。

本報告包​​含自2016年以來公佈的989項細胞療法交易的完整列表，其中包括可用的財務條款以及各方披露的實際細胞療法合作的在線記錄鏈接。此外，在條件允許的情況下，記錄還包括公司及其合作夥伴向美國證券交易委員會提交的合約文件。

本報告的引言概述了細胞治療領域的交易活動。

第一章概述了本報告。

第二章概述了自 2016 年以來的細胞治療交易活動。

第三章概述了自 2016 年以來主要的細胞治療交易，並依交易額列出。

第四章提供了最活躍的 25 家細胞治療公司的完整清單及其簡要概述，以及細胞治療交易和公開合約文件的完整清單。

第五章對自 2016 年 1 月以來已完成和已宣布的、合約文件公開的細胞治療交易進行了全面深入的審查。

第六章對自2016年1月以來簽署和公佈的細胞療法合作協議進行了全面深入的回顧。本章以具體的細胞療法技術類型進行組織。

該報告還包含大量表格和圖表，展示了自2016年以來細胞療法交易的趨勢和活動。

此外，我們還提供了一個全面的合約目錄，依公司名稱（A-Z）、合約類型和疾病治療進行分類。每個合約標題都透過網路連結連結到線上合約記錄，並在可用的情況下連結到合約文件，方便用戶輕鬆存取每個合約文件。

主要優勢

"細胞療法合作與授權協議（2016-2025）" 報告為讀者提供以下主要優勢：

• 了解自 2016 年以來的交易趨勢
• 查看細胞療法合作與許可協議（2016-2025）
• 基準分析 - 確定交易市場價值
• 財務條款 - 首付款、里程碑付款、特許權使用費
• 依公司（A-Z）、交易類型和治療領域列出交易
• 以價值為排名的熱門交易
• 最活躍的交易撮合者
• 識別每筆交易的資產描述和條款
• 存取合約文件 - 深入了解交易結構
• 盡職調查 - 評估擬議交易條款對合作夥伴公司的適用性
• 節省數百小時的研究時間。

範圍

• "細胞療法合作與許可協議（2016-2025）" 旨在幫助讀者深入了解細胞療法的發展趨勢以及全球領先的生物製藥公司所達成的協議結構。

本報告內容

• 生物製藥產業細胞療法交易趨勢
• 製藥和生物技術公司細胞療法交易記錄目錄
• 以價值排名主要的細胞療法交易
• 最活躍的細胞療法許可協議公司
• "細胞療法合作與許可協議（2016-2025）" 提供對現有交易記錄的全面訪問，包括合約文件（如有）。

分析合約有助於對以下方面進行盡職調查：

• 合約具體授予或選擇哪些權利？
• 合約實際授予合作夥伴哪些權利？
• 授予了哪些排他性權利？
• 交易的付款結構是什麼？
• 如何進行銷售和付款審計？
• 合約期限是多久？
• 如何定義合約的關鍵條款？
• 如何處理並擁有知識產權？
• 誰負責商業化？
• 誰負責開發、供應和生產？
• 如何管理保密性和資訊揭露？
• 如何解決爭議？
• 在什麼情況下可以終止合約？
• 如果所有權發生變更，會發生什麼事？
• 如何就分授權和分包條款達成協議？
• 貴公司要求使用哪些標準條款？
• 哪些標準條款會因交易對手或交易類型而異？
• 貴公司必須遵守哪個司法管轄區的法律？

目錄

摘要整理

第一章：引言

第二章：細胞療法交易趨勢

• 引言
• 歷年細胞療法交易
• 最活躍的細胞療法經銷商
• 以交易類型劃分的細胞療法交易
• 依治療領域劃分的細胞療法交易
• 依行業劃分的細胞療法交易
• 細胞療法交易條款
  • 細胞療法交易的關鍵價值
  • 細胞療法交易中的預付款
  • 細胞療法交易中的里程碑付款
  • 細胞療法特許權使用費率

第三章 - 關鍵細胞療法交易

• 引言
• 以價值排名的頂級細胞療法交易

第四章 - 最活躍的細胞療法經銷商

• 引言
• 最活躍的細胞療法經銷商
• 最活躍的細胞療法經銷商公司簡介

第五章 - 細胞療法合約交易目錄

• 引言
• 細胞療法合約交易目錄

第六章 - 依技術類型分類的細胞療法交易

• 交易目錄
• 依公司分類的細胞療法交易目錄 (AZ)
• 以交易類型分類的細胞療法交易目錄
• 依治療領域分類的細胞療法交易目錄
• 交易類型定義
• 關於研究公司
• 當前合作夥伴關係
• 當前協議
• 當前合作夥伴關係近期報告標題

Cell Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cell therapy deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of cell therapy deals from 2016 to 2025.

The report provides a detailed understanding and analysis of how and why companies enter cell therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 989 cell therapy deals announced since 2016 including financial terms where available including links to online deal records of actual cell therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cell therapy dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cell therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading cell therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cell therapy dealmaking with a brief summary followed by a comprehensive listing of cell therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cell therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cell therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific cell therapy technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cell therapy deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cell Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cell therapy collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Cell Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cell therapy trends and structure of deals entered into by leading biopharma companies worldwide.

Cell Therapy Collaboration and Licensing Deals includes:

• Trends in cell therapy dealmaking in the biopharma industry
• Directory of cell therapy deal records covering pharmaceutical and biotechnology
• The leading cell therapy deals by value
• Most active cell therapy licensing dealmakers
• Cell Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cell therapy dealmaking

• 2.1. Introduction
• 2.2. Cell therapy deals over the years
• 2.3. Most active cell therapy dealmakers
• 2.4. Cell therapy deals by deal type
• 2.5. Cell therapy deals by therapy area
• 2.6. Cell therapy deals by industry sector
• 2.7. Deal terms for cell therapy deals
  • 2.7.1 Cell therapy deals headline values
  • 2.7.2 Cell therapy deal upfront payments
  • 2.7.3 Cell therapy deal milestone payments
  • 2.7.4 Cell therapy royalty rates

Chapter 3 - Leading cell therapy deals

• 3.1. Introduction
• 3.2. Top cell therapy deals by value

Chapter 4 - Most active cell therapy dealmakers

• 4.1. Introduction
• 4.2. Most active cell therapy dealmakers
• 4.3. Most active cell therapy deals company profiles

Chapter 5 - Cell therapy contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cell therapy contracts dealmaking directory

Chapter 6 - Cell therapy dealmaking by technology type

• Deal directory
• Deal directory - Cell therapy deals by company A-Z
• Deal directory - Cell therapy deals by deal type
• Deal directory - Cell therapy deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cell therapy deals since 2016
• Figure 2: Active cell therapy dealmaking activity - 2016 - 2025
• Figure 3: Cell therapy deals by deal type since 2016
• Figure 4: Cell therapy deals by therapy area since 2016
• Figure 5: Cell therapy deals by industry sector since 2016
• Figure 6: Cell therapy deals with a headline value
• Figure 7: Cell therapy deals with an upfront value
• Figure 8: Cell therapy deals with a milestone value
• Figure 9: Cell therapy deals with a royalty rate value
• Figure 10: Top cell therapy deals by value since 2016
• Figure 11: Most active cell therapy dealmakers 2016 - 2025
• Figure 12: Cell therapy deals by technology type since 2016